Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Objectives The aim of this study was to assess the current evidence for long-acting β2-
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …

La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad
clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el …

The clinical presentation of chronic obstructive pulmonary disease (COPD) varies widely, so
treatment must be tailored according to the level of risk and phenotype. In 2012, the Spanish …

Introduction Few randomised controlled trials (RCTs) have directly compared long-acting
muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual maintenance therapies for …

COPD is often misdiagnosed and inappropriately treated in many patients. COPD is a
distinct disease from adult-onset asthma; however, some patients with COPD may present …

Background and objective Retrospective claims data in patients with chronic obstructive
pulmonary disease (COPD) initiating maintenance therapy with inhaled fixed-dose …

Background Chronic obstructive pulmonary disease (COPD) are managed predominantly in
primary care. However, key opportunities to optimize treatment are often not realized due to …

Background Researchers have yet to obtain conclusive evidence differentiating among fixed-
dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β …

Blood-based biomarkers for diagnosing and determining the progression of COPD remain
disappointingly elusive. Although there have been some advances in nonblood-based …